Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niclosamide + camostat
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Niclosamide + camostat is a combination of two small molecule drugs. Niclosamide is an anthelmintic agent primarily used to treat tapeworm (cestode) infections in humans. It acts by disrupting oxidative phosphorylation in the mitochondria of parasites, leading to ATP depletion and death of the worm. Beyond its antiparasitic use, niclosamide has demonstrated activity against various signaling pathways (such as Wnt/β-catenin, mTORC1, STAT3, NF-κB, and Notch), suggesting potential utility in cancer and viral infections[1][2][6]. Camostat is a serine protease inhibitor most commonly used for chronic pancreatitis and has been investigated for its ability to inhibit TMPRSS2—a host cell protease involved in viral entry—making it a candidate for antiviral therapy including COVID-19. The combination has been explored experimentally as a potential antiviral regimen due to their complementary mechanisms targeting both viral entry (camostat) and replication or host response pathways (niclosamide).
- Brand names
- Yomesan
- Other names
- NICCAM
02
Targets
OXPHOS (Mitochondrial OXPHOS complexes)TMPRSS2 (Transmembrane protease serine 2)Mechanistic target of rapamycin complex 1STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on niclosamide + camostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niclosamide + camostat.